Screener
Haemonetics HAE Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Selling, general and administrative | 118,941 | 110,719 |
| Amortization of acquired intangible assets | 10,204 | 11,392 |
| Total operating expenses | 145,345 | 138,372 |
| Operating income | 57,458 | 53,872 |
| Interest and other expense, net | (9,884) | (8,703) |
| Income before provision for income taxes | 47,574 | 45,169 |
| Provision for income taxes | 14,564 | 11,138 |
| Net income | $33,010 | $34,031 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's operating income?
- Haemonetics (HAE) reported operating income of $57.46M in Q2 2026.
- How has Haemonetics's operating income changed year-over-year?
- Haemonetics's operating income increased by 6.7% year-over-year, from $53.87M to $57.46M.
- What is the long-term trend for Haemonetics's operating income?
- Over 3 years (2022 to 2025), Haemonetics's operating income has grown at a 40.1% compound annual growth rate (CAGR), from $80.75M to $221.82M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Haemonetics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude